The 14th Global Drug Delivery Formulation Summit is the leading event to look at innovative solutions and the greatest challenges in pharmaceutical development today.
Going to the summit?
The event will highlight pharmaceutical development challenges from small molecules and biologics, new technologies with concepts and case studies being presented in a number of innovative areas.
Cambridge Consultants' Harshal Shah, head of oncology innovations for global medical technology will be presenting on the key area for innovation in minimally invasive drug delivery.
Direct-to-Organ Drug Delivery – Opportunities, Challenges, and Ideas.
Date | 31 May 2023
Time | 10:00 - 10:30am
Track | Solutions Spot Light
Speakers | Harshal Shah, Head of Global BioPharma Commercial, Cambridge Consultants | Paramesh Natarajan, Biology and Biomedical Engineer, Cambridge Consultants
R&D pipeline across the biopharma industry is diversifying at rapid pace with new modalities and new class of drugs becoming significant part of their overall research strategy. Increasingly we are observing a need for delivering drug locally in difficult to access anatomy such as heart, brain, spine, kidneys across different therapeutic areas including oncology, CNS, autoimmune and number of rare diseases. The preference will always be to delivery these drugs with minimally invasive approach. Our team evaluated challenges involved in developing device technologies and new procedure for delivering such complex drugs localized to organs, tumours or tissues and developed innovative ideas and concepts that could be deployed in specific situations. This talk will focus on few select ideas and our thought process in design and development of such delivery platforms and procedures.
Speaker Bio | Harshal is part of our global medical division based out of Boston, with more than a decade of experience in medical device development, product life cycle strategy, and innovation management. He has significant expertise in oncology patient journey, economics of cancer care and innovations in oncology. He has a Bachelor of Mechanical Engineering degree from Nirma Institute of Technology in India, an MBA from Syracuse University, New York, and he recently completed a post graduate program in cancer biology and therapeutics development from Harvard Medical School.